Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Summit links with Taiwan firm for lead product

This article was originally published in Scrip

Executive Summary

Summithas reached an agreement with the Taiwanese firm Orient Pharma to co-develop a buccal formulation of its lead product SMT D001. An oral formulation of the product, a combination of two marketed products with dry mouth as a side-effect, is in Phase II trials for sialorrhoea (excessive drooling) in Parkinson's disease patients. However, Summit has now suspended recruitment in this programme and will switch to the buccal formulation for future trials. Orient, a subsidiary ofOrient Europharma, will fund the development of the buccal formulation and also gains exclusive development and commercialisation rights in Asia and Australasia as part of the tie-up. It will cover all future costs related to the product in its territories, with Summit retaining rights in the rest of the world, where the UK firm is seeking partners.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC021453

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel